“No longer will an antibody fail to reach its full therapeutic and diagnostic potential, due to physical instability or function.” 

Dr. Fred Stevens  – Co-Founder

AD-Venture is a groundbreaking joint venture formed by three innovative companies.

This strategic collaboration leverages the unique strengths of each partner to
redefine possibilities in computational biology, advanced biologics design, and ideation.

AD-Venture’s mission is to harness human intuition, scientific rigor, and artificial intelligence (AI) to develop novel biological sequences with superior stability, functionality, and scalability.

AffiBio-UIA™ Algorithms

The Solution to Protein Biodesign Challenges

FACT: Proteins, specifically antibody proteins, have to be refrigerated to maintain their efficacy whether for diagnostic or therapeutic applications.

Currently, there is no known protein amino acid sequence alignment user interface tool known that is available for every-day scientists to solve thermal stability problems leading to improved affinity performance of antibody proteins.

StableBody Technologies, LLC is offering its rational protein design technology as a User Interface Application for scientists everywhere working with amino acid sequence alignment data in protein design and engineering from their lab bench base with built-in automation components for design work.

Benefits of Thermodynamic Stabilization:

Leadership Team

H. Rossiter Horn, R.Ph.
Founder, and Chief Executive Officer

Harry has over 25 years of experience in the biotech and pharmaceutical industries, working with both Fortune 50 and start-up companies. He has owned a successful consulting business focused on strategic business, clinical and corporate development, directed a successful strategic clinical development program at SangStat Medical Corporation, was responsible for a multi-million-dollar sales territory with Ortho Biotech, and enjoyed a successful sales career at Knoll Pharmaceuticals. Mr. Horn holds a B.S. (R.Ph.) degree in Pharmacy from the Temple University School of Pharmacy and a B.S. in Biology from the University of Scranton.

Joe Firca, PH.D.
Founder, Chief Scientific Officer

Joe has more than 35 years of extensive operating and product development knowledge and is a recognized leader in the life science and biotechnology arena in matters of research, technology assessment, and regulatory issues. He has a combined 18 years leading research groups at Baxter International and Abbott Laboratories. Throughout his distinguished career, Dr. Firca has contributed to numerous publications and patents. Some of his contributions include co-development of the first automated DNA synthesizer; Abbott liaison to Amgen, Inc. for a joint collaboration on DNA probes for infectious diseases; systems integration for major instrumentation in blood donor screening; and the development of numerous approved immunoassays for the detection of infectious disease agents. Most recently he served as Adjunct Associate Professor in Biomedical Engineering and Associate Director of Corporate Relations at the McCormick School of Engineering, Northwestern University. Dr. Firca holds a Ph.D. in Microbiology (Microbial Genetics) from the University of Cincinnati, an M.S. in Microbiology (Mycology) from Duquesne University and a B.S. in Biology from Xavier University and has done postdoctoral work at Argonne National Laboratory.

Ed Corrigan, PH.D.
Founder, Chairman and Chief Financial Officer

Ed has had extensive financial management, regulatory compliance, and retail and investment banking experience in both the private and public sectors. He is the founder of a successful early stage Food Safety, Human Clinical, and Veterinary Diagnostics  biotechnology company that has been in business 15 years. He has overseen a biotechnology laboratory and supervised the development of a hand-held biosensor instrument now on the market. His training is in public finance and economics. Dr. Corrigan holds a B.A degree from Rutgers College, and M.A. (Economics) and Ph.D. (International Economics) degrees from the University of Denver.

Daniel Kaye
Independent Director

Dan has more than 40 years of executive business experience in finance, auditing, governance & risk management, and is a retired Managing Partner – Assurance at Ernst and Young LLP, Chicago where he was responsible for more than 1,600 Assurance professionals in 10 offices across 12 states. Mr. Kaye currently is a member of the Board of Directors for Alliance Bernstein Holdings NYSE (AB), AXE Equitable Holdings NYSE (EQH) and CME Group.

In addition to the Leadership Team, StableBody Technologies, LLC has Assembled a Board of Advisors with Expertise in Software Development, Protein Engineering, Microbiology, and Project Management.